Cell therapy for acute lung injury using lung derived trypsin resistant pluripotent cells

2015 Fiscal Year Final Research Report

• Project/Area Number: 25670665
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Anesthesiology
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: TANAKA Sonomi 東京医科歯科大学, 医学部附属病院, その他 (80644103)
• Co-Investigator(Kenkyū-buntansha): 山本 寛人 東京医科歯科大学, 学内共同利用施設等, 助教 (80632174)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 急性肺傷害

Outline of Final Research Achievements

We studied the phenotype of the cells derived from rat lung tissue by trypsin treatment for 16 h, and we evaluated the efficacy of cell therapy using these cells for mouse acute lung injury model. The lung derived trypsin resistant cells had positivity for CD29 and CD90. Transcription of TIMP 1,4 and alpha-1 anti-trypsin were abundant. which might be related with tolerance to proteinases. When these cells were administered via nasal route to the lipopolysaccharide induced mice acute lung injury model, the activity of neutrophil elastase in the lung was reduced. These results suggested a possibility of these cells as a therapeutic approach to acute lung injury, but further study is needed to establish efficacy of this methodology.

Free Research Field

麻酔科学